SAB Biotherapeutics (SABS) Total Non-Current Liabilities (2020 - 2026)

SAB Biotherapeutics has reported Total Non-Current Liabilities for 7 years, with the latest figure at $15.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 1.66% year-over-year to $15.1 million; the trailing twelve-month figure through Mar 2026 stood at $15.1 million (down 1.66% YoY), and the FY2025 full-year result was $15.7 million, up 32.47% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $15.1 million, down from $15.7 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $24.4 million in Q1 2022, with the low at $11.7 million in Q2 2024.
• Historically, Total Non-Current Liabilities has averaged $16.1 million across 5 years, with a median of $15.4 million in 2025.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 466.41% — and 2023, when it slumped 41.17%.
• SAB Biotherapeutics' Total Non-Current Liabilities stood at $19.5 million in 2022, then slipped by 23.86% to $14.9 million in 2023, then retreated by 20.39% to $11.8 million in 2024, then soared by 32.47% to $15.7 million in 2025, then declined by 3.67% to $15.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $15.1 million (Q1 2026), $15.7 million (Q4 2025), and $16.0 million (Q3 2025), per Business Quant data.